GlassScriptPhysician profile
David N Kim
NPI 1568433498
$7,404.85
in general payments reported to CMS, 2019-2025
43 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $561 · 2021: $966 · 2022: $1,567 · 2023: $1,328 · 2024: $1,206 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,659.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,318.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $823.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $819.78 | 2021-2025 | |
| Lilly USA, LLC | $545.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $377.44 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $283.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $246.96 | 2019-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $232.58 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $207.35 | 2022-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.95 | 2022-2025 | Xifaxan |
| Shield Therapeutics INC | $202.19 | 2022-2025 | Accrufer |
| Abbott Laboratories | $163.69 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Eisai INC. | $133.26 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $126.23 | 2022-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.